GRAIL’s Cancer Test Won the Safety Vote. Reimbursement Is the Bet.
A 6-4 split on effectiveness means FDA approval, if it comes, is only the first gate investors need to think through.
Politics
Shopify’s 7% Rally Reveals the Real Battle: Who Owns the Agentic Checkout?
Amazon is building a wall around its customers. Shopify is renting its rails to everyone. One of these strategies compounds for a decade.
Five Things That Will Move Markets This Week
AutoZone, KB Home, Costco earnings, the September flash PMIs, and a two-day run of Treasury auctions all land before Friday’s close.
Eli Lilly Is Spending Its Obesity Billions on a Women’s Health Bet
GLP-1 cash flow is funding a new franchise in bone health and endometriosis, while the oral weight-loss pill Foundayo races toward a 2027 global rollout.
Meta’s Muse Books the Flight. Who Loses the Commission?
After a 6.55% surge, the real question is which middlemen get cut first.
Homebuilders Face a Rate Wall Before the Fed Decides
Construction spending at a three-year low, mortgage rates at a 2026 high, and BLDR getting kicked out of the S&P 500: the short case is building itself.
Aon Is Borrowing $17 Billion for USI. Can It Afford to Be Right Twice?
The NFP integration record earns Aon some credibility, but the debt load is real and the clock starts now.
The September Countdown Is Priced Wrong
Freeport restarts soon, EU storage is below seasonal norms, and the Russian LNG cutoff clock is running. The TTF-to-Henry-Hub spread is the clearest trade in energy right now.
CRM Reports in Four Days. The Only Number That Matters.
Agentforce ARR grew 205% last quarter. August 26 reveals whether that was a peak or a floor.
The July Flush Was a Fund, Not a Fact
SanDisk’s selloff was flow, not fundamentals. Understanding that distinction is the trade.
- 1
- 2